scholarly journals Effect of Topical Clove (Syzygium aromaticum (L.) Merr. & L.M.Perry) Gel on Premature Ejaculation: A Pilot Randomized Double-Blind Placebo-Controlled Clinical Trial

2021 ◽  
Author(s):  
Ahmad Reza Sharifi Olounabadi ◽  
Fereidoun Khayyamfar ◽  
Mohammad Kamalinejad ◽  
Mahmood Salesi ◽  
Fatemeh Alijaniha ◽  
...  
Keyword(s):  
Premature Ejaculation ◽  
Outcome Measurement ◽  
Sexual Disorders ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Syzygium Aromaticum ◽  
Topical Formulation ◽  
Double Blind ◽  
Ejaculation Latency ◽  
Intravaginal Ejaculation Latency Time

Premature ejaculation is one of the most common sexual disorders worldwide without a satisfying treatment. In this study, we investigated the efficacy of a topical formulation of clove oil in premature ejaculation patients. Eligible patients were randomly divided into two groups to use either Syzygium aromaticum (SA) 1% gel or placebo gel 10 minutes before the intercourse for a period of 8 weeks. Outcome measurement were Premature Ejaculation Diagnostic Tool (PEDT) and International Index of Erectile Function (IIEF) questionnaires in addition to Intravaginal Ejaculation Latency Time (IELT). A total number of 22 (11 patients in each group) participants completed the study. At the end of the intervention, the IELT scores changed from 29.84 ± 18.59 to 97.09 ± 91.86 and 42.51 ± 13.98 to 52.45 ± 32.7 seconds in SA gel and placebo groups, respectively (p-value = 0.003). Also, the changes of PEDT scores in the SA gel group (from 14 ± 3.55 to 9.2 ± 4.56) comparing to that of placebo gel group (from 14.63 ± 3.61 to 13.5 ± 3.78) was significantly different (p-value =0.001). Moreover, results of IIEF questionnaire revealed significant improvement of “Intercourse Satisfaction” in SA gel group (p-value = 0.016). No adverse event was observed. It seems that SA gel could be beneficial in the treatment of premature ejaculation; however, it should be further evaluated in larger studies.  

scholarly journals Discontinuation of Dapoxetine Treatment in Patients with Premature Ejaculation: A 2-Year Prospective Observational Study

2016 ◽  
Vol 9 (1) ◽  
pp. 66-66
Author(s):  
H. Park ◽  
◽  
N. Park ◽  
Keyword(s):  
Side Effects ◽  
Prospective Observational Study ◽  
Premature Ejaculation ◽  
Treatment Options ◽  
Drop Out ◽  
Discontinuation Rate ◽  
Oral Agent ◽  
Pde5 Inhibitors ◽  
Ejaculation Latency ◽  
Intravaginal Ejaculation Latency Time

Objective: Although dapoxetine is the only oral agent approved for premature ejaculation (PE) and is very effective, its discontinuation rate is high compared to PDE5 inhibitors for ED treatment. We assessed discontinuation rate of dapoxetine in PE and the reasons for discontinuation. Design and Method: The study enrolled 182 patients (mean age 38.2). The PE type (life-long or acquired), self-estimated intravaginal ejaculation latency time (IELT), IIEF-EF questionnaire, and medical history were checked in all patients. The patients were evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation. Results: Of the patients, 9.9% were still in treatment after 2 years. The discontinuation rates at 1, 3, 6, 12, and 24 months were 26.4, 35.2, 17.6, 8.2, and 2.7%, respectively. Cumulatively, 79.1% of the patients discontinued the treatment within 6 months. After 12 months, however, the discontinuation rate dropped sharply. The reasons for discontinuation were cost (29.9%), disappointment that PE is not a curable disease and dapoxetine was needed whenever he had sex (25%), side effects (11.6%), low efficacy (9.8%), to seek other treatment options (5.5%), and unknown (18.3%). Patients with acquired PE (vs. life-long), IELT >2 min before treatment, older than 50 years, taking PDE-5 inhibitors, and IIEF-EF <26 tended to discontinue early and had high drop-out rates. Conclusions: Only 9.9% patients continued treatment after 24 months, while 79.1% discontinued within 6 months. The main reasons for discontinuation were not related to its side effects or low efficacy.

scholarly journals Impact of Metabolic Syndrome on the Occurrence of Premature Ejaculation

2016 ◽  
Vol 9 (1) ◽  
pp. 74-74
Author(s):  
S. Jeh ◽  
◽  
S. Choi ◽  
S. Kam ◽  
J. Hwa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Premature Ejaculation ◽  
Multivariate Logistic Regression Analysis ◽  
Predisposing Factor ◽  
Symptom Index ◽  
Effective Prevention ◽  
Male Health ◽  
Ejaculation Latency ◽  
Intravaginal Ejaculation Latency Time

Objective: The aim of this study was to investigate the effect of MetS in pathogenesis of ejaculatory symptoms, particularly PE. In addition, we evaluate the other risk factors associated with PE. Design and Method: Between January 2010 and July 2014, we analyzed the medical records of men who had visited to our Urology clinic for screening of male health. To evaluate the risk factors including MetS for PE, patients were assessed self-reported intravaginal ejaculation latency time (IELT), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF), the Male Sexual Health Questionnaire (MSHQ-EjD) for Ejaculatory Dysfunction, NIHChronic Prostatitis Symptom Index (NIH-CPSI), and Androgen Deficiency in the Aging Male (ADAM) scales. Premature ejaculation defined as self-reported IELT <1 minute, and metabolic syndrome diagnosed by modified National Cholesterol Education Program’s Third Adult Treatment Panel (NCEP ATP III) criteria. Results: Among the total of 1029 men, 74 patients (7.2%) were considered to have PE (ejaculation within 1 min) and 111 patients (10.8%) were considered to have MetS. The multivariate logistic regression analysis showed that IIEF OS score (OR 0.670, P <0.001), NIH-CPSI pain score (OR 1.070, P = 0.048), NIH-CPSI voiding score (OR 1.167, P = 0.040), and metabolic syndrome (OR 2.187, P = 0.023) were significantly related to the prevalence of PE. Conclusions: MetS may be an important predisposing factor for the development of PE, and consequently its effective prevention and treatment could also be important for the prevention of PE.

Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial

2018 ◽  
Vol 33 (3) ◽  
pp. 305-315 ◽  
Author(s):  
Mohammad-Hadi Farahzadi ◽  
Ehsan Moazen-Zadeh ◽  
Emran Razaghi ◽  
Mohammad-Reza Zarrindast ◽  
Reza Bidaki ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trials ◽  
Specific Treatment ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Urine Test ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Methamphetamine Dependence ◽  
Significant Difference

Background: Riluzole is a glutamate regulator and effective in treatment of neuropsychiatric conditions. Aims: We assessed riluzole for treatment of methamphetamine dependence. Methods: In this randomized, double-blind, placebo-controlled clinical trial, male outpatients with methamphetamine dependence who were 18–65 years old received either 50 mg riluzole ( n=34) or placebo ( n=54) twice daily for 12 weeks. Patients were excluded in case of comorbid serious medical conditions or neurologic disorders, comorbid psychiatric disorders other than methamphetamine dependence requiring specific treatment interventions, simultaneous positive urine test result for substances of abuse other than methamphetamine, smoking >3 days per week, simultaneous consumption of medications which are contraindicated or have interaction with riluzole. Results: Concerning primary outcomes, the cumulative mean number of attended weekly visits was higher in the riluzole arm compared with the placebo arm approaching a statistically significant difference (riluzole, median (range)=13.00 (2.00–13.00); placebo=4.00 (2.00–13.00); Mann-Whitney U=505.00, p-value=0.073), and the weekly measured rate of positive methamphetamine urine test results was significantly lower in the riluzole arm by the end of the study (riluzole=1 (5.00%), placebo=9 (45.00%), p-value=0.004). Patients in the riluzole arm experienced significantly greater improvement on all the craving, withdrawal, and depression measures regarding mean score changes from baseline to endpoint. No significant difference was detected between the two arms in terms of incidence of adverse events. Conclusion: Future randomized clinical trials are needed to investigate proper dosing strategy in a more inclusive sample.

scholarly journals Risk factors of premature ejaculation and its influence on sexual function of spouse

2021 ◽  
Vol 31 (1) ◽  
Author(s):  
Hu Li ◽  
Pan Gao ◽  
Jingjing Gao ◽  
Xu Wu ◽  
Guodong Liu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Sexual Function ◽  
Premature Ejaculation ◽  
Negative Attitude ◽  
Control Group ◽  
Female Sexual Function ◽  
Female Partners ◽  
Ejaculation Latency ◽  
Intravaginal Ejaculation Latency Time ◽  
The Relationship

Abstract Background Premature ejaculation (PE) is a multifactorial problem with a complicated aetiology that has detrimental effects on female partners’ sexual function. However, there is a lack of studies on the relationship between the factors related to PE and female sexual dysfunction (FSD) in China. We aimed to identify and explore the relationship between the factors associated with PE and FSD. Results Ultimately, information was collected from 761 couples: 445 couples with PE complaints and 316 couples without PE complaints. The mean ages of the men with and without PE complaints were 36.29 ± 9.87 years and 31.48 ± 10.77 years, respectively. Female partners in the group with PE complaints reported lower total and subdomain female sexual function index (FSFI) scores, and approximately 65% of them were diagnosed with FSD (vs. control group: 31.96%). A PE duration of more than 14 months, a self-estimated intravaginal ejaculation latency time (self-estimated IELT) less than 2 min, a negative attitude towards PE problems, men’s introversion, and men’s depression were risk factors for FSD in the PE group. Conclusions PE affects not only the patient himself but also the spouse. Comprehensive analysis reveals a clear relationship and interaction between female sexual function and PE. Moreover, in PE treatment, we should not ignore the occurrence of FSD and its impact and should emphasize the treatment of couples together.

Sign in / Sign up

Export Citation Format

Share Document